Skip to main content

Table 1 Demographic and clinical characteristics of 10 diagnosed FD patients

From: Multidisciplinary approach to screening and management of children with Fabry disease: practice at a Tertiary Children’s Hospital in China

ID

Age at diagnosis (years)

Age at first symptom (years)

Sex

Proband α-Gal A (normal  > 2.4 umol/l/h)

Proband lyso-GL-3 (normal  < 1.11 ng/ml)

GLA NM_000169.2 Nucleotide alteration, Protein change

Zygosity (Segregation)

ACMG classification

Phenotypes from pedigree analysis

α-Gal A from pedigree analysis (normal > 2.4 umol/l/h)

Lyso-GL-3 from pedigree analysis (normal < 1.11 ng/ml)

Treatment

ERT

Adjunctive treatment

01

0.7

0.7

Male

0.4

32.63

c.195-1G > A

Hemi (F, WT;Aff. M, het)

LP

Pain

1.21

8.24

No

Potassium citrate

02

7.2

3.6

Female

3.7

1.69

c.640-801G > A (also known as IVS4 + 919 G > A)

Het (Aff. F, Hemi; M, WT)

P

Sinus arrhythmia, High left ventricular voltage

1.24

3.43

No

Topiramate

03

11.4

8.4

Male

0.42

100.48

c.277 G > A, p.Asp93Asn

Hemi (F, WT; Aff. M, het)

P

None

0.57

7.60

No

None

04

10.4

3.5

Male

0.41

92.98

c.140G > A, p.W47X

Hemi (F, WT; Aff. M, het)

LP

Pain

NA

6.17

Yes

Oxcarbazepine

05

16.0

16.0

Male

0.23

2.29

c.335 G > A, p.R112H

Hemi (F, WT; Aff. M, het)

LP

None

NA

1.00

No

None

06

0.1

N

Male

1.64

 < 0.55

c.257A > T, p.Y86T

Hemi (F, NA; Aff. M, het)

LP

Pain

2.73

2.77

No

None

07

0.3

N

Male

1.42

 < 0.55

c.215 T > C, p.M72T (novel variant)

Hemi (F, WT; Aff. M, het)

LP

None

NA

 < 0.55

No

None

08

15.6

11.7

Male

0.25

76.06

c.974G > A, p.G325D

Hemi (F, NA; Aff. M, het)

P

None

NA

4.56

Yes

ARB, Carbamazepine,

Calcitriol, Ketoacid, Febuxostat,

Psychiatry referral

09

13.6

7.5

Male

0.3

104.76

c.100A > C, p.Asn34His

Hemi (F, WT; Aff. M, het)

LP

Pain, Dermatological angiokeratoma, Corneal verticillata, Hypertension, Left ventricular hypertrophy, Diarrhea

NA

ND

Yes

Carbamazepine,

Psychiatry referral

10

15.7

4.5

Male

0.26

113.57

c.679C > T, p.Arg227X

Hemi (F, NA; Aff. M, het)

P

Proteinuria

NA

NA

Yes

ACEI,

Carbamazepine

  1. α-Gal A, α-galactosidase A; ACEI, angiotensin-converting enzyme inhibitor; ACMG, American College of Medical Genetics and Genomics; Aff., affected; ARB, angiotensin receptor blocker; ERT, enzyme replacement therapy; F, father; FD, Fabry disease; Hemi, hemizygous; Het, heterozygous; ID, individual identifier; Lyso-GL-3, globotriaosylsphingosine (deacylated form of GL-3); LP, likely pathogenic; M, Mother; NA, not available; P, pathogenic; WT, wild type